

## **Jian Ding**

### **Personal**

Full name: Jian DING  
Title: Director of the Oncology Center  
Education: Doctor  
Phone: +86-2168077961  
E-mail: jding@simm.ac.cn  
Postal Code: 201203  
Mailing Address: Shanghai Institute of Materia Medica, Chinese Academy of Sciences,  
555 Zuchongzhi Road, Pudong, Shanghai

### **Education**

1975.11-1978.11, Jiangxi Medical University, Nanchang, China, B.S. in Pathology  
1980.9-1983.9, Medical University of China, Shenyang, China, M.A. in Pathology  
1986.10-1991.03, Kyushu University, Fukuoka, Japan, Ph.D. in Pathology

### **Work Experience**

1986.10-1992.1 Kyushu University Visiting scholar  
1992.2-1994.4 Shanghai Institute of Materia Medica, Postdoctoral fellow  
1994.4-1995.11 Shanghai Institute of Materia Medica, Principal Investigator/Associate  
Researcher  
1995.12-now, Shanghai Institute of Materia Medica, Principal Investigator/Researcher  
1996.3-2004.11 Shanghai Institute of Materia Medica, Deputy Director/Researcher  
2004.12-2013.12 Shanghai Institute of Materia Medica, Director/Researcher  
2005.1-2012.1 State key Laboratory of Drug Research, Director, Professor/Researcher  
2014.06-2019.05 Shanghai Institute of Materia Medica, Director of Academic  
Committee  
2014.01-now Dean of School of Pharmacy, Chinese Academy of Sciences  
2020.08-now Director of the Oncology Center, Shanghai Institute of Materia Medica

### **Research Directions**

Molecular targeted Anti-tumor drug development, Mechanism study & Biomarker Research & Development

### **Social Titles**

1. 2006.12-now, Acta Pharmacologica Sinica, Editor-in-chief;
2. 2007.01-now, European Journal of Pharmacology, Editorial board member;
3. 2007.01-now, Journal of Ethno pharmacology, Editorial board member;
4. 2013.01-2019.1, Molecular Pharmacology, Editorial Advisory Board (EAB) member;
5. 2017.04-2022.01, Vice Chairman of Chinese Pharmaceutical Association;
6. 2012.07-2021.07, Vice Chairman of the Chinese Pharmacological Society;
7. 2017.04-now, Chairman of Shanghai Pudong New Area Science Association

### **Awards & Honors**

1. 2020, the Second National Innovation Competition Award (Medal)
2. 2017, First Prize of Shanghai Pharmaceutical Technology (2/6)
3. 2016, Outstanding Scientific and Technological Achievement Award of Chinese Academy of Sciences
4. 2016, Tan Jiazhen Life Science Achievement Award
5. 2015, Advanced Science and Technology Worker of Chinese Academy of Sciences
6. 2013, National Natural Science Award
7. 2012, National outstanding science and technology workers
8. 2009, National Natural Science Award, 2rd prize
9. 2008, Prize of Scientific and Technological Progress of Ho Leung Ho Lee Foundation
10. 2007, 2010 National Natural Science Award (Shanghai)
11. 2006, Wu Jieping Medical-Paul Janssen Pharmaceutical Research Prize
12. 2005, Top ten scientific and technological elites (Shanghai)
13. 2004, 2005 Excellent Supervisor of Chinese Academy of Sciences

14. 2003, National Science & Technology Award, 2nd prize
15. 2003, Shanghai Science & Technology Award
16. 2001, Fourth International Debio-CCRF Award, 1st Prize

### **Selected Publications**

1. Zhang X, Wang Y, Zhang X, Shen Y, Yang K, Ma Q, Qiao Y, Shi, Wang Y, Xu, Yang B, Ge G, Hu L, Kong X, Yang Ch, Chen Y\*, **Ding J\***, Meng L\*. Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3K $\alpha$  inhibitors. *Signal Transduct Target Ther.* 2023; 8:153.
2. Zhang T, Qu R, Chan Sh, Lai M, Tong L, Feng F, Chen H, Song T, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Shen Y, Sun Y, Chen Y, Geng M, Ding K\*, **Ding J\***, Xie H\*. Discovery of a Novel Third-Generation EGFR Inhibitor and Identification of a Potential Combination Strategy to Overcome Resistance. *Mol Cancer.* 2020;19(1):90.
3. Wang X, Zhang M, Ping F, Liu H, Sun J, Wang Y, Shen A, **Ding J\***, Geng M\*. Identification and therapeutic intervention of coactivated anaplastic lymphoma kinase, fibroblast growth factor receptor 2, and ephrin type-A receptor 5 kinases in hepatocellular carcinoma. *Hepatology.* 2019;69(2):573-586
4. Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, Wei R, Zheng X, Liu Zh, Zhang X; Yang H, Hao B, Shen Y, Su Y, Cong X, Huang M, Tan M\*, **Ding J\***, Geng M\*. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-aberrant Solid Tumors, *Cell*, 2018;175(1):186-199.
5. Lian Q, Xu J, Yan S, Huang M\*, Ding H, Sun X, **Ding J\***, Sun B\*, Geng M\*. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. *Cell Res.* 2017;27(6):784-800.
6. Yue X, Ai J, Xu Y, Chen Y, Huang M, Yang X, Hu B, Zhang H, He Ch, Yang X, Tang W, Peng X, Dong L, Wang H, Fan J\*, **Ding J\***, Geng M\*. Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. *Hepatology.* 2017;65(6):1948-1962.
7. Chen Y, Wang Y, Zhang J, Su Y, Shen Y, Jiang D, Hou Y, Geng M\*, **Ding J\***. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. *Nat Commun.* 2017 8(1):27.
8. Dai X, Yan J, Fu X, Pan Q, Sun D, Xu Y, Wang J, Nie L, Tong L, Shen A, Zheng M, Huang M, Tan M, Liu H, Huang X\*, **Ding J\***, Geng M\*. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. *Clin Cancer Res.* 2017;23(20):6267-6278.
9. Liu H, Ai J, Shen A, Chen Y, Wang X, Peng X, Chen H, Shen Y, Huang M\*, **Ding J\***, Geng M\*. c-Myc alteration determines the therapeutic response to FGFR inhibitors. *Clin Cancer Res.* 2017; 23(4):974-984.
10. Zeng H, Qu J, Jin N, Xu J, Lin C, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M\*, **Ding J\***, Geng M\*. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylases inhibitors in breast cancer. *Cancer Cell*, 2016;30(3):459-73.